

# 2024 CGA-IGC Annual Meeting

The Collaborative Group of the Americas  
on Inherited Gastrointestinal Cancer



November 14-16, 2024  
*Philadelphia*

**FINAL  
PROGRAM  
E-BOOK**

# TABLE OF CONTENTS



**2024 CGA-IGC  
Annual Meeting**

November 14-16, 2024

*Philadelphia*

WELCOME ADDRESS .....	3
FLOORPLAN.....	4
GENERAL INFORMATION .....	5
PROGRAM AT A GLANCE .....	8
SOCIAL ACTIVITIES .....	10
SCIENTIFIC PROGRAM .....	11
THURSDAY, NOVEMBER 14, 2024.....	11
FRIDAY, NOVEMBER 15, 2024.....	13
SATURDAY, NOVEMBER 16, 2024.....	15
INVITED SPEAKERS.....	16
SPONSORS & EXHIBITORS .....	17
SPONSORED INDUSTRY SYMPOSIA .....	18
SPONSORS & EXHIBITORS DIRECTORY .....	19
ADVERTS .....	29
SAVE THE DATE – #CGAIGC25.....	41

# WELCOME ADDRESS



**2024 CGA-IGC  
Annual Meeting**

November 14-16, 2024

*Philadelphia*

Dear Colleagues and Friends,

I am thrilled to welcome you to our **28<sup>th</sup> CGA-IGC Annual Meeting in Philadelphia, PA, on November 14 – 16<sup>th</sup>, 2024.**

The CGA-IGC Annual Meeting is the preeminent meeting for genetic counselors, physicians, scientists, advanced practice providers, trainees, and others involved in the diagnosis, treatment, and care of individuals with hereditary gastrointestinal cancer predisposition syndromes.

Our meeting will feature unmatched scientific content including the latest innovations and breakthroughs in the clinical care and management of hereditary gastrointestinal cancer predisposition syndromes, which will be delivered from experts from around the world. We will also feature cutting edge research through multiple oral abstract plenary sessions and poster sessions. Additionally, we will continue to support networking for all of our members, including a specific focus on supporting trainees and early career professionals in the field.

I am excited to bring this year's CGA-IGC Annual Meeting back to the East Coast, to Philadelphia. Not only is Philadelphia my hometown, but it is a fantastic city with a myriad of historical sites, outstanding restaurants, and cultural icons, that I hope you will be able to explore when here.

I am looking forward to welcoming you to Philadelphia in the Fall of 2024 for another outstanding CGA-IGC Annual Meeting.

On behalf of the CGA-IGC Meeting Planning Committee,



Bryson Katona, MD, PhD  
CGA-IGC President & Chair of the Meeting Planning Committee


# FLOORPLAN



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

Philadelphia



My Faulty Gene	1
ConnectMyVariant	2
Invitae	3
Project DNA	4
Tempus	5
ClearNote Health	6
Exact Sciences	7
Springworks Therapeutics	8
ColoWrap	9
Ambry Genetics	10
Penn Medicine Lynch Syndrome Program	11
New Zealand Familial Gastrointestinal Cancer Service	12
Jacqueline Rush Foundation	13

Fight CRC	14
Mayberry Memorial	15
AliveAndKickn	16
Dana-Farber Cancer Institute	17
FORCE-Facing Our Risk of Cancer Empowered	18
Helen F. Graham Cancer Center & Research Institute	19
Braintree A Part Of Sebelo Pharmaceuticals	20
Lynsight	21
Natera	22
CCARE Lynch Syndrome	23
National Comprehensive Cancer Network (NCCN)	24
Myriad Genetics	25

# GENERAL INFORMATION



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

Philadelphia

### MEETING DATES | DESTINATION | VENUE | WEBSITE

November 14-16, 2024 | Philadelphia, PA, USA | Sheraton Philadelphia Downtown Hotel | <https://cgaigcmeeting.org/>

### MEETING HOURS

#### Registration Desk Opening Hours

Thursday, November 14, 2024	06:00 – 18:00
Friday, November 15, 2024	06:00 – 18:00
Saturday, November 16, 2024	07:00 – 15:00

#### Daily Agenda Hours

Thursday, November 14, 2024	07:00 – 19:00
Friday, November 15, 2024	07:00 – 19:00
Saturday, November 16, 2024	08:00 – 16:00

#### Exhibition Opening Hours

Thursday, November 14, 2024	07:00 – 18:00
Friday, November 15, 2024	07:00 – 18:00
Saturday, November 16, 2024	08:00 – 17:00

### PRACTICAL INFORMATION FOR THE MEETING

#### Time Zone

Philadelphia, Pennsylvania operates according to Eastern Daylight Time (EDT) during November, which is 5 hours behind the Coordinated Universal Time (UTC-5).

#### Language of the Meeting

The official language of the 2024 CGA-IGC Annual Meeting is English. No translations will be available during the sessions.

#### Wi-Fi Network for Meeting Participants

We are pleased to offer complimentary Wi-Fi access to all CGA-IGC 2024 participants. Please check for the network name and password from the Wi-Fi signs in the meeting area.



#### Dress Code for Meeting Participants

The dress code for the 2024 CGA-IGC Annual Meeting is business formal or business casual for all occasions unless stated otherwise.

#### F&B

Coffee breaks as stated in the meeting scientific program will be served in the Exhibition Area.



In the meeting scientific program, there are 2 sponsored breakfast industry symposia (on Thursday and Friday), 3 sponsored lunch industry symposia (on Thursday, Friday, and Saturday).



During these sponsored symposia, the sponsoring company will provide the F&B for the participants attending the session. The F&B stations for these meal services will be located inside the Industry Session Hall.

### CME / CEU ACCREDITATION

For the 2024 CGA-IGC Annual Meeting, relevant applications have been made for CME and CEU accreditations for the attendees. For the accreditation process and claim of credits, the attendees will be required to fill in the Post-Meeting Survey and the Online Evaluation Form, which will be shared with all participants after the meeting.

#### CEU Accreditation for Genetic Counselors

The National Society of Genetic Counselors (NSGC) has authorized to offer up to **2.467 CEUs** or **24.67 Category 1 contact hours** for the activity 2024 CGA-IGC Annual Meeting. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor recertification.

### CME ACCREDITATION FOR PHYSICIANS

#### Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 19.75 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### American Board of Surgery (ABS) Continuous Certification Program

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

19.75 ABS MOC

#### Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 19.75 contact hours.

#### Canadian Board of Genetic Counselling CME - CBGC CEC

The 2024 CGA-IGC Annual Meeting has been approved by the Canadian Board of Genetic Counselling (CBGC) for **17.08 CECs**.

# GENERAL INFORMATION



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

Philadelphia

### INFORMATION FOR SPEAKERS & PRESENTERS

All invited speakers, oral abstract presenters, and industry session speakers will be able to preview and edit (if necessary) their slide sets at the Speaker Preview Corner in Liberty B. After previewing and editing the slides, you are kindly asked to deliver your presentation(s) to the technical desk in the main Plenary Session Hall (Liberty CD) at least 4 hours prior to the start time of your session(s). If the session is the first session in the morning, please upload your presentation the day before.

#### Speakers' Preview Corner Opening Hours:

Thursday, November 14, 2024	06:00 – 18:00
Friday, November 15, 2024	06:00 – 18:00
Saturday, November 16, 2024	07:00 – 15:00

### MEETING MATERIALS FOR PARTICIPANTS

#### Name Badges & Mini Program

The name badges and the mini programs will be distributed from the Registration desk. All participants are kindly asked to wear their name badges throughout the Annual Meeting.

#### Meeting Bags & Inclusions

The Annual Meeting bags include notepads, pens, CGA-IGC, and industry bag inserts. They will be distributed from the Registration desk.

#### Certificates of Attendance

The certificates of attendance will be sent to all participants as a PDF file via e-mail after the Annual Meeting.

#### Certificates of Presentation

The presenters of oral and poster abstracts will be eligible to get a certificate of presentation which will be sent to the presenters upon request after the Meeting. You may contact the Meeting Organizing Secretariat (Ms. Cagla Avcioglu at [cavcioglu@kenes.com](mailto:cavcioglu@kenes.com)) to receive your presentation certificates.

#### Final Program E-Book & Abstracts' E-Book

A Final Program E-Book (PDF) including all relevant information about the Annual Meeting and the Abstracts' E-Book (PDF) giving our attendees access to the abstracts during the presentations will be available for display on the mobile application of the Annual Meeting.

### Official Abstracts Publication in Familial Cancer Journal

All presented abstracts of the CGA-IGC 2024 will be published online in the Familial Cancer Journal. The publication process will start after the Annual Meeting ends and when it is published all participants will be provided with the relevant URL to access the published journal.

### Mobile Application

The Meeting mobile application is prepared for you to navigate through the Meeting details with ease and enhance your participation. You may download it through IOS/App Store or Android/Google Play via the QR codes below.



Download from  
IOS/App Store



Download from  
Android/Google Play

The event code for the mobile application is **CGAIGC24**. To log into the mobile app, please use the credentials that were sent to you via e-mail before the Meeting.

### DISCLAIMER

#### Liability & Insurance

The CGA-IGC and the Meeting Organizing Secretariat cannot accept liability for personal accidents or loss of or damage to the private property of participants. Upon registration, participants agree that neither the CGA-IGC nor the Meeting Organizing Secretariat assumes any liability. Participants are advised to take out their own personal travel and health insurance for their trip.

#### Safety and Security

Bags and/or suitcases must not be left unattended at any time whether inside or outside the Meeting venue and session hall(s). As all hotels do, we strongly recommend our participants to use their safety deposit boxes for their valuables.

# GENERAL INFORMATION



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

*Philadelphia*

### MEETING ORGANIZING SECRETARIAT



Office: Kenes M+

#### **Registration, Accommodation & Travel Inquiries**

Ms. Neyir Utugen, Registration & Accommodation Manager

E-mail: [nutugen@kenes.com](mailto:nutugen@kenes.com)

#### **Scientific Inquiries**

Ms. Cagla Avcioglu, Scientific Program Coordinator

E-mail: [cavcioglu@kenes.com](mailto:cavcioglu@kenes.com)

#### **Sponsorship & Exhibition Inquiries**

Mr. Daghan Sivaci, Industry Liaison & Sales Manager

E-mail: [dsivaci@kenes.com](mailto:dsivaci@kenes.com)

#### **Promotional Inquiries**

Ms. Gizem Unsalan, Senior Marketing Coordinator

E-mail: [gunsalan@kenes.com](mailto:gunsalan@kenes.com)

#### **Any Other Inquiries**

Ms. Lara Volkan, Project Manager

E-mail: [lvolkan@kenes.com](mailto:lvolkan@kenes.com)

# PROGRAM AT A GLANCE



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

*Philadelphia*

Legend	Scientific Sessions
	Named Lectureship Sessions
	Abstract Sessions
	Sponsored Industry Symposia

*\*All Industry Symposia will be held in a separate hall from the plenary hall. Industry Symposia Hall is "Liberty A".*

Thursday, November 14, 2024	
Session Time	Plenary Hall - Liberty C&D
07:00 - 07:45	Breakfast Symposia Sponsored by Myriad Genetics
08:00 - 08:10	Welcome & Housekeeping <i>Bryson Katona, CGA-IGC President</i>
08:10 - 09:55	Session I: Genetic Counseling Conundrums <i>Moderators: Zach Foda &amp; Michelle Savage McSweeney</i>
09:55 - 10:15	AM Break
10:15 - 11:15	Debate: Pancreatic Cancer Early Detection <i>Moderators: Dana Zakalik &amp; Shenin Sanoba</i>
11:15 - 12:15	Named Lecture: Lemuel Herrera Lecture <i>Moderator: Hannah Campbell &amp; Michelle Springer</i> Diversity in Genetic Counseling, <i>Erica Ramos</i>
12:15 - 13:45	LUNCH BREAK
12:30 - 13:30	Lunch Symposia Sponsored by SpringWorks
13:45 - 15:15	Presidential Plenary I <i>Moderators: Peter Stanich &amp; Bryson Katona</i>
15:15 - 16:00	PM Break
15:25 - 15:55	CCARE Lynch Poster Walk <i>Moderators: Zsofia Stadler &amp; Megha Ranganathan</i>
16:00 - 17:00	Named Lecture: Henry Lynch Lecture <i>Moderators: Jacquelyn Powers &amp; Daniel Li</i> Cancer risk management and interception opportunities in BRCA1/2 carriers, <i>Susan Domchek</i>
17:00 - 18:00	Hereditary Live <i>Moderators: Joshua Sommovilla</i>
18:00 - 19:00	Poster Session 1
19:30 - 22:30	Social Event <i>*Separate ticket is required</i>

# PROGRAM AT A GLANCE



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

Philadelphia

Legend	Scientific Sessions
	Named Lectureship Sessions
	Abstract Sessions
	Sponsored Industry Symposia

*\*All Industry Symposia will be held in a separate hall from the plenary hall. Industry Symposia Hall is "Liberty A".*

Friday, November 15, 2024	
Session Time	Plenary Hall - Liberty C&D
07:00 - 07:45	Breakfast Symposia Sponsored by Ambray Genetics
08:00 - 08:10	Welcome & Housekeeping <i>Bryson Katona, CGA-IGC President</i>
08:10 - 09:40	Session II: Lynch Syndrome Moderators: <i>Mohammad Abbass &amp; Veroushka Ballester</i>
09:40 - 10:00	AM Break
10:00 - 10:45	Named Lecture: Jeremy Jass Lecture Moderators: <i>Sanjeevani Arora &amp; Aparajita Singh</i> 25 years of CDH1: history, current controversies, and future opportunities, <i>Jeremy Davis</i>
10:45 - 12:30	Session III: International Updates Moderators: <i>Pooja Dharwadkar &amp; Tatiana Johnson</i>
12:00 - 13:20	LUNCH BREAK
12:10 - 13:10	Lunch Symposia Sponsored by Immunovia
13:20 - 14:50	Presidential Plenary II Moderators: <i>Bryson Katona &amp; Beth Dudley</i>
14:50 - 15:10	PM Break
15:10 - 16:55	Session IV: Polyposis Moderators: <i>Douglas Riegert-Johnson and Julie Moskowitz</i>
17:00 - 18:00	Jeopardy Moderators: <i>Michael Hall &amp; Maegan Roberts</i>
18:00 - 19:00	Poster Session 2

Saturday, November 16, 2024	
Session Time	Plenary Hall - Liberty C&D
08:00 - 08:10	Welcome & Housekeeping <i>Bryson Katona, CGA-IGC President</i>
08:10 - 10:10	Session V: Hot Topics in Hereditary GI Cancer Moderators: <i>Gautam Mankaney &amp; Kristin Zelley</i>
10:10 - 10:30	AM Break
10:30 - 11:30	Session VI: Pancreatic Cancer Early Detection Moderators: <i>Lisen Axell &amp; Joel Gabre</i>
11:30 - 12:15	Named Lecture: Bert Vogelstein Lecture Moderators: <i>Jennifer Weiss &amp; Daniel Luba</i> Non-invasive colorectal cancer screening and the potential application to hereditary GI cancer syndromes, <i>Aasma Shaukat</i>
12:15 - 13:45	LUNCH BREAK
12:30 - 13:30	Lunch Symposia Sponsored by Invitae
13:45 - 15:15	Presidential Plenary III Moderators: <i>Beth Dudley &amp; Elana Levinson</i>
15:15 - 16:15	CGA-IGC Business Meeting & Presidential Transition <i>Bryson Katona &amp; Michael Hall</i> Post Meeting Wrap Up <i>Beth Dudley</i>

# SOCIAL ACTIVITIES



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

Philadelphia

### COMMITTEE MEETINGS

**Date** : Wednesday, November 13, 2024  
**Time** : 14:30 - 16:00  
**Location** : Mezzanine Level

Education Committee	“Salon 2”
Membership Committee	“Salon 3”
Research Committee	“Salon 4”
Communications Committee	“Salon 5”
Justice, Equity, Diversity & Inclusion Committee	“Salon 6”

### SOCIAL ACTIVITIES

#### CGA-IGC Awards Reception

**Date** : Wednesday, November 13, 2024  
**Time** : 16:30 - 18:30  
**Location** : Horizon Rooftop

*Invitation-only event is for attendees who have already RSVPed.*

#### Philly Phest with CGA-IGC & Fight CRC

**Date** : Thursday, November 14, 2024  
**Time** : 19:30 - 22:30  
**Location** : Sheraton Philadelphia Hotel / Horizon Rooftop  
*A separate ticket is required.*



**FIGHT**  
COLORECTAL CANCER

#### CCARE Lynch Poster Walk

Supported by CCARE Lynch Syndrome  
**Date** : Thursday, November 14, 2024  
**Time** : 15:25 - 15:55  
**Location** : Poster Area – Liberty B



#### Poster Session 1

Supported by OSU/James Cancer Center  
**Date** : Thursday, November 14, 2024  
**Time** : 18:00 - 19:00  
**Location** : Poster Area – Liberty B



#### Poster Session 2

Supported by OSU/James Cancer Center  
**Date** : Friday, November 15, 2024  
**Time** : 18:00 - 19:00  
**Location** : Poster Area – Liberty B



# SCIENTIFIC PROGRAM



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

Philadelphia

Legend	Scientific Sessions
	Named Lectureship Sessions
	Abstract Sessions
	Sponsored Industry Symposia
*All Industry Symposia will be held in a separate hall from the plenary hall. Industry Symposia Hall is "Liberty A".	

Thursday, November 14, 2024	
Session Time	Plenary Hall - Liberty C&D
07:00 - 07:45	<p>Myriad Genetics Sponsored Breakfast 1</p> <p>Exploring Models for Large-Scale Point-of-Care Genomic Testing in Gastrointestinal Cancers and Beyond</p> <p>Moderator: <i>Shrutika Yeola MMSc, CGC</i> <i>Myriad Genetics</i></p> <p>Speakers: <i>Ann Marie Miller, MS, CGC</i> <i>Myriad Genetics</i> <i>Michael J Hall, MD, MS</i> <i>Chairman, Department of Clinical Genetics</i> <i>Fox Chase Cancer Center</i> <i>Matthew Yurgelun, MD, FASCO, CGAF</i> <i>Director, Lynch Syndrome Center</i> <i>Director of Clinical Research, DFCI Center for Cancer Genetics &amp; Prevention</i> <i>Christine Drogan, MS, LCGC</i> <i>Associate Director of the GI Cancer Risk and Prevention Clinic</i> <i>UChicago</i> <i>Dana Farengo Clark, MS, LCGC</i> <i>Senior Genetic Counselor</i> <i>Penn Medicine</i></p>
08:00 - 08:10	<p>Welcome &amp; Housekeeping</p> <p><b>Bryson Katona, CGA-IGC President</b></p>
08:10 - 09:55	<p><b>Session I: Genetic Counseling Conundrums</b></p> <p>Moderators: <i>Zach Foda &amp; Michelle Savage McSweeney</i></p> <p>Genetic counseling and genetic testing challenges at the end of life, <i>Lisa Madlensky</i></p> <p>Q&amp;A</p> <p>Germline genetic testing and transplant eligibility, <i>Katie Lang</i></p> <p>Q&amp;A</p> <p>Impact and implications of variant reclassification in cancer genetics, <i>Sukh Makhnoon</i></p> <p>Q&amp;A</p> <p>How We Do It - Mainstreaming Genetic Testing for CRC Patients, <i>Matthew F Kalady &amp; Josie Baker &amp; Kathryn Baker</i></p>
09:55 - 10:15	<p><b>Break</b></p>
10:15 - 11:15	<p><b>Debate: Pancreatic Cancer Early Detection</b></p> <p>Debate: BRCA1/2, PALB2, ATM carriers without a family history of pancreatic cancer: To screen or not to screen the pancreas?</p> <p>Moderators: <i>Dana Zakalik &amp; Shenin Sanoba</i></p> <p>Yes, <i>Aimee Lucas</i></p> <p>No, <i>Randy Brand</i></p> <p>Rebuttals and Q&amp;A</p>
11:15 - 12:15	<p><b>Named Lecture: Lemuel Herrera Lecture</b></p> <p>Moderator: <i>Hannah Campbell &amp; Michelle Springer</i></p> <p>Introduction, <i>Hannah Campbell</i></p> <p>Diversity in Genetic Counseling, <i>Erica Ramos</i></p> <p>Q&amp;A</p> <p>Reflections From A Patient And Research Advocate, <i>Wenora Johnson</i></p> <p>Q&amp;A</p>
12:15 - 13:45	<p><b>LUNCH BREAK</b></p>

# SCIENTIFIC PROGRAM



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

Philadelphia

Legend	Scientific Sessions
	Named Lectureship Sessions
	Abstract Sessions
	Sponsored Industry Symposia
*All Industry Symposia will be held in a separate hall from the plenary hall. Industry Symposia Hall is "Liberty A".	

Thursday, November 14, 2024	
Session Time	Plenary Hall - Liberty C&D
12:30 - 13:30	<p>SpringWorks Sponsored Lunch 1</p> <p>OGSIVEO: An Approved Treatment for Adults with Progressing Desmoid Tumors Who Require Systemic Treatment <i>Dr. Bassan Allan</i></p>
13:45 - 15:15	<p>Presidential Plenary I Moderators: Peter Stanich &amp; Bryson Katona</p> <p>Trends in Lifespan and Cause of Death Among Patients with Familial Adenomatous Polyposis, <i>Brian Christopher Brajcich</i> Reproductive Decision Making and Maternal and Fetal Risk in Individuals with Germline (CDH1) Variants, <i>Cassidy Rose Bowden</i> Gastric and lobular breast cancer prevalence in (CTNNA1) heterozygotes identified via multigene panel testing, <i>Jennifer Herrera Mullar</i> Clinicopathologic and allele-specific analysis of germline and somatic MUTYH alterations in a pan-cancer cohort, <i>Matteo Repetto</i> Outcomes of Intestinal Transplantation for Familial Adenomatous Polyposis Associated Intraabdominal Desmoid Disease, <i>Mohamed Elshawy</i> Predictors of Invasive Signet Ring Cell Carcinoma in (CDH1) Carriers – Results from the GASTRIC Consortium, <i>Ophir Gilad</i></p>
15:15 - 16:00	PM Break
15:25 - 15:55	<p>CCARE Lynch Poster Walk Moderators: Zsofia Stadler &amp; Megha Ranganathan</p> <p>Small Bowel Surveillance Assessed by Video Capsule Endoscopy in Asymptomatic Lynch Syndrome Subjects, <i>Giulia Martina Cavestro</i> Genotype Specific Lynch Associated Cancer Risk Compared to the General Population: Results from a Nationwide Database, <i>Timothy Yen</i> Endometrial Intraepithelial Neoplasia (EIN) as a Precursor in Lynch Syndrome-Associated Endometrial Carcinoma, <i>Hadley Reid</i> Efficacy of Urinary Tract Cancer Surveillance Among Patients with Lynch Syndrome, <i>Mehul Trivedi</i> Immunogenic profiles in Lynch syndrome colorectal cancers are consistent across different mismatch repair gene defects, <i>Noah Cornelis Helderman</i></p>
16:00 - 17:00	<p>Named Lecture: Henry Lynch Lecture Moderators: Jacquelyn Powers &amp; Daniel Li</p> <p>Introduction, <i>Jacquelyn Powers</i> Cancer risk management and interception opportunities in BRCA1/2 carriers, <i>Susan Domchek</i> Q&amp;A Assessment of Pancreatic Cancer Screening in High-Risk Patients: Experience from a Community Health System, <i>Jacqueline Neminski</i> Outcomes of Risk Assessment and Genetic Testing for Patients with Early-onset Adenomas, <i>W. Curtis Weaver</i> A Blood-based, Multiplex Protein Biomarker Signature Shows Superior Performance in Detection of Early-stage Pancreatic Ductal Adenocarcinoma (PDAC), <i>Norma Palma</i> Peutz-Jeghers Syndrome and Lung Cancer Risk: Does the Risk Meet the Threshold for Lung Cancer Screening?, <i>Jennifer M. Weiss</i> Insurance Coverage and Denials of Guideline-Recommended Colorectal Cancer Genetic Testing, <i>Edward Esplin</i></p>
17:00 - 18:00	<p>Hereditary Live Moderators: Joshua Sommovilla</p> <p>Panelists: <i>Ajay Bansal, Matthew Yurgelun, Jessica Long</i> Case Presentation 1 Case Presentation 2</p>
18:00 - 19:00	Poster Session 1
19:30 - 22:30	<p>Social Activity - Philly Phest *seperate ticket is required</p>

# SCIENTIFIC PROGRAM



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

Philadelphia

Legend	Scientific Sessions
	Named Lectureship Sessions
	Abstract Sessions
	Sponsored Industry Symposia

*\*All Industry Symposia will be held in a separate hall from the plenary hall. Industry Symposia Hall is "Liberty A".*

Friday, November 15, 2024	
Session Time	Plenary Hall - Liberty C&D
07:00 - 07:45	<p>Ambry Genetics Sponsored Breakfast 2</p> <p>New and Notable Efforts Towards the Accurate Diagnosis of Hereditary Gastrointestinal Cancer: Genes, Phenotypes, and Test Improvements</p> <p>Frankie Fann, MS, LCGC Genomic Science Liaison Ambry Genetics</p>
08:00 - 08:10	<p>Welcome &amp; Housekeeping</p> <p><b>Bryson Katona, CGA-IGC President</b></p>
08:10 - 09:40	<p><b>Session II: Lynch Syndrome</b> <i>Moderators: Mohammad Abbass &amp; Veroushka Ballester</i></p> <p>Gynecologic controversies in Lynch syndrome: utility of screening, contraceptive use, and surgical timing and extent, <b>Lee-May Chen</b></p> <p>Q&amp;A</p> <p>Segmental colectomy is the preferred surgical approach in Lynch syndrome, <b>Carlos Vaccaro</b></p> <p>Extended colectomy is the preferred surgical approach in Lynch syndrome, <b>Jose Guillem</b></p> <p>Rebuttals and Q&amp;A</p>
09:40 - 10:00	<b>AM Break</b>
10:00 - 10:45	<p><b>Named Lecture: Jeremy Jass Lecture</b> <i>Moderators: Sanjeevani Arora &amp; Aparajita Singh</i></p> <p>Introduction, <b>Sanjeevani Arora</b></p> <p>25 years of CDH1: history, current controversies, and future opportunities, <b>Jeremy Davis</b></p> <p>Q&amp;A</p>
10:45 - 12:30	<p><b>Session III: International Updates</b> <i>Moderators: Pooja Dharwadkar &amp; Tatiana Johnson</i></p> <p>Updates from the 2024 IGCLC Meeting, <b>Carla Oliveira, Portugal</b></p> <p>Q&amp;A</p> <p>Updates from the 2024 Insight Annual Meeting, <b>Francesc Balaguer, Spain</b></p> <p>Q&amp;A</p> <p>Comprehensive characterization of screening strategies for Lynch syndrome from a large cohort of colorectal cancer individuals of Latin American, <b>Mev Dominguez Valentin</b></p> <p>Q&amp;A</p>
12:00 - 13:20	<b>LUNCH BREAK</b>
12:10 - 13:10	<p>Immunovia Sponsored Lunch 2</p> <p>Increasing access to High-Risk Pancreatic Cancer Screening; Lessons learned from implementation of early detection tests within a community based high risk program</p> <p>Moderator: Norma Palma, PhD</p> <p>Landscape of Early Detection Tests of High-Risk Pancreatic Cancer, <b>Dr. Ora Gordon</b>, Executive Director of Cancer Services, Saint John's Cancer Institute &amp; Disney Family Cancer Center</p> <p>High-Risk Pancreatic Cancer Surveillance Programs in a Community Setting, <b>Miles Picus</b>, Genetic Counselor and Program Coordinator of Providence's high-risk pancreatic cancer screening and prevention program</p>
13:20 - 14:50	<p><b>Presidential Plenary II</b> <b>Moderators: Bryson Katona &amp; Beth Dudley</b></p> <p>Development And Validation Of An Exosome-Based And Machine Learning Powered Liquid Biopsy For Early-Onset Colorectal Cancer: The [ENCODE] Study, <b>Alessandro Mannucci</b></p> <p>"It would just make everything easier": Patient perspectives on the potential of mHealth to reduce the burden of care management in Lynch syndrome, <b>Jordan Clawson</b></p> <p>Parent-of-origin assignment of pathogenic variants without parental data, <b>Kasmintan A Schrader</b></p> <p>Influence of Preoperative Lynch Syndrome Diagnosis on the Extent of Surgery in Patients with Colon Cancer, <b>Mohammad Ali Abbass</b></p> <p>Modeling uptake of aspirin (ASA) and NSAIDs in Lynch syndrome (LS) to elucidate barriers to chemoprevention of hereditary cancers, <b>Michael Hall</b></p> <p>Risks of Colorectal Cancer Among TP53 Mutation Carriers in the LiFT-UP Study, <b>Stephen B Gruber</b></p>
14:50 - 15:10	<b>PM Break</b>

# SCIENTIFIC PROGRAM



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

Philadelphia

Legend	Scientific Sessions
	Named Lectureship Sessions
	Abstract Sessions
	Sponsored Industry Symposia
*All Industry Symposia will be held in a separate hall from the plenary hall. Industry Symposia Hall is "Liberty A".	

Friday, November 15, 2024	
Session Time	Plenary Hall - Liberty C&D
14:50 - 15:10	PM Break
15:10 - 16:55	<p><b>Session IV: Polyposis</b>  <i>Moderators: Douglas Riegert-Johnson and Julie Moskowitz</i></p> <p>Thyroid cancer risk and surveillance across hereditary polyposis syndromes, <b>Steven Waguespack</b>                      Q&amp;A</p> <p>Juvenile polyposis syndrome with and without a driver gene mutation: Same syndrome different phenotypes or different syndromes?,  <b>Suzanne MacFarland</b>                      Q&amp;A</p> <p>Emerging polyposis syndromes: risks and management both within and outside the colon, <b>Melyssa Aronson</b>                      Q&amp;A</p> <p>How We Do It - Management of complex upper gastrointestinal lesions in FAP: selection, technical considerations, benefits, and limitations,  <b>Carol Burke &amp; Amit Bhatt &amp; Michael Cruise</b></p>
17:00 - 18:00	<p><b>Jeopardy</b>  <i>Moderators: Michael Hall &amp; Maegan Roberts</i></p>
18:00 - 19:00	<b>Poster Session 2</b>

# SCIENTIFIC PROGRAM



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

Philadelphia

Legend	Scientific Sessions
	Named Lectureship Sessions
	Abstract Sessions
	Sponsored Industry Symposia
*All Industry Symposia will be held in a separate hall from the plenary hall. Industry Symposia Hall is "Liberty A".	

Saturday, November 16, 2024	
Session Time	Plenary Hall - Liberty C&D
08:00 - 08:10	Welcome & Housekeeping <b>Bryson Katona, CGA-IGC President</b>
08:10 - 10:10	<b>Session V: Hot Topics in Hereditary GI Cancer</b> <i>Moderators: Gautam Mankaney &amp; Kristin Zelley</i>  Hepatobiliary cancers: germline genetic associations and when to test, <b>Kirk Wangenstein</b> Q&A Gastrointestinal cancer risks and management in Li-Fraumeni syndrome, <b>Kara Maxwell</b> Q&A Care for transgender individuals with a hereditary GI cancer Syndrome, <b>Rachel Hodan</b> Q&A Genetic discrimination: Updates and implications for genetic counseling, <b>Jennifer Wagner</b> Q&A
10:10 - 10:30	<b>AM Break</b>
10:30 - 11:30	<b>Session VI: Pancreatic Cancer Early Detection</b> <i>Moderators: Lisen Axell &amp; Joel Gabre</i>  MRI for pancreatic cancer screening: pros, cons, and other considerations, <b>Carla Harmath</b> Q&A Blood-based tests for pancreatic cancer screening in high-risk individuals: What should be used and how?, <b>Fay Kastrinos</b> Q&A
11:30 - 12:15	<b>Named Lecture: Bert Vogelstein Lecture</b> <i>Moderators: Jennifer Weiss &amp; Daniel Luba</i>  Introduction, <b>Jennifer Weiss</b> Non-invasive colorectal cancer screening and the potential application to hereditary GI cancer syndromes, <b>Aasma Shaukat</b> Q&A
12:15 - 13:45	<b>LUNCH BREAK</b>
12:30 - 13:30	<b>Invitae Sponsored Lunch 3</b>  Exploring mainstreaming models for cancer risk assessment and genetic testing Moderator: Kate McReynolds, APRN, MS, MSN, ANP-BC, AGN-BC  Daniel Luba, MD Jill Polk, MS, CGC
13:45 - 15:15	<b>Presidential Plenary III</b> <i>Moderators: Beth Dudley &amp; Elana Levinson</i>  The Incidence of Pancreatic Cancer in Women with a BRCA1 or BRCA2 mutation, <b>Bryson W Katona</b> The At-Risk Cancer Genetic Syndrome Identification (ARCAGEN-ID) project: A systems approach to scale-up Lynch syndrome identification, <b>Xavier Llor</b> Development of a Clinical Decision Support Tool for Cancer Risk Assessment for Trans and Gender-Diverse Patients with Lynch Syndrome, <b>Joyce Gong</b> Predictors of Positive Genetic Testing in Adenomatous Polyposis, <b>Peter P Stanich</b> Patient preferences for selective exclusion of high-risk genes on multigene panel testing, <b>Samuel Levy</b> Impact of RNA Sequencing on Variant Classification: Experience at a High-Volume Cancer Genetics Center, <b>Sydney Rudowski</b>
	<b>CGA-IGC Business Meeting &amp; Presidential Transition</b> <i>Bryson Katona &amp; Michael Hall</i>  <b>Post Meeting Wrap Up</b> <i>Beth Dudley</i>

# INVITED SPEAKERS



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

*Philadelphia*



Melyssa Aronson  
Mount Sinai Hospital/Zane  
Cohen Centre  
Canada



Francesc Balaguer  
Hospital Clinic of Barcelona  
Spain



Randall Brand  
University of Pittsburgh  
United States



Lee-may Chen  
UCSF Helen Diller Family  
Comprehensive Cancer Center  
United States



Jeremy Davis  
NCI  
United States



Susan Domchek  
University of Pennsylvania  
School of Medicine  
United States



Jose Guillem  
UNC Chapel Hill  
United States



Carla Harmath  
The University Of Chicago  
United States



Rachel Hodan  
Stanford Health Care  
United States



Wenora Johnson  
Fight CRC  
United States



Fay Kastrinos  
Columbia University  
United States



Katie Lang  
Vanderbilt University Medical  
Center  
United States



Aimee Lucas  
Mount Sinai  
United States



Suzanne MacFarland  
Children's Hospital Of  
Philadelphia  
United States



Lisa Madlensky  
University of California San  
Diego  
United States



Sukh Makhnoon  
UT Southwestern Medical  
Center  
United States



Kara Maxwell  
University of Pennsylvania  
School of Medicine  
United States



Carla Oliveira  
I3s, Institute Of Research And  
Innovation In Health, University  
of Porto, Portugal



Erica Ramos  
Genome Medical, Inc.  
United States



Aasma Shaukat  
NYU Langone Health  
United States



Carlos Vaccaro  
Hospital Italiano  
Argentina



Jennifer Wagner  
Penn State University  
United States



Steven Waguespack  
University of Texas MD  
Anderson Cancer Center  
United States



Kirk Wangenstein  
Mayo Clinic  
United States

# SPONSORS & EXHIBITORS



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

Philadelphia

We would like to thank the sponsors and exhibitors below for their invaluable contribution to the 28<sup>th</sup> CGA-IGC Annual Meeting (CGA-IGC 2024)

### Platinum Sponsors



### Gold Sponsors



### Sponsors & Exhibitors



# SPONSORED INDUSTRY SESSIONS



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

Philadelphia

### MYRIAD GENETICS INDUSTRY SYMPOSIUM

**Date** : November 14 / Thursday  
**Time** : 07:00 – 07:45  
**Title** : Exploring Models for Large-Scale Point-of-Care Genomic Testing in Gastrointestinal Cancers and Beyond  
**Moderator** : Shrutika Yeola MMSc, CGC, Myriad Genetics  
**Speakers** : Ann Marie Miller, MS, CGC, Myriad Genetics  
Michael J Hall, MD, MS, Chairman, Department of Clinical Genetics, Fox Chase Cancer Center  
Matthew Yurgelun, MD, FASCO, CGAF, Director, Lynch Syndrome Center  
Director of Clinical Research, DFCI Center for Cancer Genetics & Prevention  
Christine Drogan, MS, LCGC, Associate Director of the GI Cancer Risk and Prevention Clinic, UChicago  
Dana Farengo Clark, MS, LCGC, Senior Genetic Counselor, Penn Medicine



### SPRINGWORKS INDUSTRY SYMPOSIUM

**Date** : November 14 / Thursday  
**Time** : 12:30 – 13:30  
**Title** : OGSIVEO: An Approved Treatment for Adults with Progressing Desmoid Tumors Who Require Systemic Treatment  
**Speaker** : Dr. Bassan Allan



### AMBRY GENETICS INDUSTRY SYMPOSIUM

**Date** : November 15 / Friday  
**Time** : 07:00 – 07:45  
**Title** : New and Notable Efforts Towards the Accurate Diagnosis of Hereditary Gastrointestinal Cancer: Genes, Phenotypes, and Test Improvements  
**Speaker** : Frankie Fann, MS, LCGC, Genomic Science Liaison, Ambry Genetics



### IMMUNOVIA INDUSTRY SYMPOSIUM

**Date** : November 15 / Friday  
**Time** : 12:10 – 13:10  
**Title** : Increasing access to High-Risk Pancreatic Cancer Screening; Lessons learned from implementation of early detection tests within a community based high risk program  
**Moderator** : Norma Palma, PhD  
**Speakers** : Landscape of Early Detection Tests of High-Risk Pancreatic Cancer, Dr. Ora Gordon, Executive Director of Cancer Services, Saint John's Cancer Institute & Disney Family Cancer Center  
High-Risk Pancreatic Cancer Surveillance Programs in a Community Setting, Miles Picus, Genetic Counselor and Program Coordinator of Providence's high-risk pancreatic cancer screening and prevention program



### INVITAE INDUSTRY SYMPOSIUM

**Date** : November 16 / Saturday  
**Time** : 12:30 – 13:30  
**Title** : Exploring mainstreaming models for cancer risk assessment and genetic testing  
**Moderator** : Kate McReynolds, APRN, MS, MSN, ANP-BC, AGN-BC  
**Speakers** : Daniel Luba, MD, Jill Polk, MS, CGC



# SPONSORS & EXHIBITORS DIRECTORY



2024 CGA-IGC  
Annual Meeting

November 14-16, 2024

*Philadelphia*

## AliveandKick'n

Web : <https://www.aliveandkickn.org/>

AliveandKick'n aims to improve the lives of individuals and families affected by Lynch syndrome and associated cancers through research, education and screening.



## Ambry Genetics

Web : [www.ambrygen.com](http://www.ambrygen.com)

Ambry Genetics, a part of REALM IDx, excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind the genetic disease. Our unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate, and pharmaceutical partners, means we are first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions. We care about what happens to real people, their families, and the people they love, and remain dedicated to providing them and their clinicians with deeper knowledge and fresh insights, so together they can make informed, potentially life-altering healthcare decisions. For more information, please visit [www.ambrygen.com](http://www.ambrygen.com).



## Braintree, a part of Sebel Pharmaceuticals

Web : [www.sebelapharma.com](http://www.sebelapharma.com)

Braintree, a part of Sebel Pharmaceuticals, is a specialty pharmaceutical company that develops, manufactures, and markets products in the field of Gastroenterology. Products include SUFLAVE™ (approved June 15, 2023), SUTAB®, SUPREP® Bowel Prep Kit, GoLYTELY®, NuLYTELY®, Motofen®, Analpram HC® and Lotronex® Tablets. Visit us at [www.sebelapharma.com](http://www.sebelapharma.com)





# SPONSORS & EXHIBITORS DIRECTORY



2024 CGA-IGC  
Annual Meeting

November 14-16, 2024

Philadelphia

## ColoWrap

Address : 3333 Durham-Chapel Hill Blvd Ste. A200 Durham, NC 27707  
Phone : 1-888-815-3376  
Web : <https://www.colowrap.com/>



ColoWrap is a non-invasive abdominal compression device used during colonoscopy to minimize looping and facilitate intubation. The device shortens procedure time, minimizes manual pressure and repositioning, and reduces endoscopy staff MSK pain by 85%. ColoWrap 360 is a companion AI tool that identifies patients most likely to benefit from ColoWrap.

## ConnectMyVariant

Address : 1511 3rd Ave, Suite 600, Seattle, WA 98101  
Email : [info@connectmyvariant.org](mailto:info@connectmyvariant.org)  
Web : <https://connectmyvariant.org/>



ConnectMyVariant is an educational organization that supports early detection and the prevention efforts of individuals and families with hereditary disease. It provides unique value by leveraging family connections to help people identify other at-risk relatives and help those relatives access genetic testing and tailored preventative medical care. It brings people with the same genetic risk together to share experiences, find common ancestors, and help each other get the best medical care. ConnectMyVariant also works to increase awareness of hereditary disease and the benefits of family outreach among physicians and other health care providers who provide primary and prevention care.

## Dana-Farber Cancer Institute - The Lynch Syndrome Center

The Lynch Syndrome Center at Dana-Farber Cancer Institute is a unique multi-disciplinary center that specializes in coordinating all aspects of care for people with Lynch syndrome.

Launched in 2019, our Center features clinical experts from various specialties with particular expertise in Lynch syndrome, provides personalized longitudinal care and support for individuals and families with Lynch syndrome while utilizing state-of-the-art diagnostic tools and conducts cutting edge research

on Lynch syndrome and translate research breakthroughs to leading-edge prevention and treatment methods. We offer genetic testing and counseling, coordinated care from expert specialists, a community for patients and provider education and events.



# SPONSORS & EXHIBITORS DIRECTORY



2024 CGA-IGC  
Annual Meeting

November 14-16, 2024

Philadelphia

## Exact Sciences

Address : 5505 Endeavor Lane - Madison, WI 53719

Web : [www.exactsciences.com](http://www.exactsciences.com)

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its product pipeline with the launch of the OncoExTra™ and Riskguard™ tests to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company's website at [www.exactsciences.com](http://www.exactsciences.com).

## Fight Colorectal Cancer (Fight CRC)

Address : 134 Park Central Square #210 Springfield, MO 65806

Phone : (703) 548-1225

Web : <https://fightcolorectalcaner.org/>

Fight Colorectal Cancer (Fight CRC) is the leading patient-empowerment and advocacy organization in the United States, providing balanced and objective information on colon and rectal cancer research, treatment, and policy. Fight Colorectal Cancer's mission is "We fight to cure colorectal cancer and serve as relentless champions of hope for all affected by this disease through informed patient support, impactful policy change, and breakthrough research endeavors. It takes passionate, informed people to advocate. We believe this advocacy will lead to research."

## FORCE-Facing Our Risk of Cancer Empowered

Address : 16057 Tampa Palms Blvd. W, PMB #373, Tampa, FL 33647

Web : <https://www.facingourrisk.org>

FORCE is a national nonprofit organization for individuals and families affected by hereditary cancers. Our website is <https://www.facingourrisk.org>

# SPONSORS & EXHIBITORS DIRECTORY



2024 CGA-IGC  
Annual Meeting

November 14-16, 2024

Philadelphia

## Helen F. Graham Cancer Center & Research Institute

Address : 4701 Ogletown-stanton Rd, Newark, Delaware, 19713, US

Web : <https://christianacare.org/us/en/facilities/helen-f-graham-cancer-center>



The Genetic Risk Assessment Program at ChristianaCare's Center for Medical Genetics & Genomics, Helen F. Graham Cancer Center & Research Institute in Newark Delaware offers consultation, genetic testing and support for families who may have a hereditary risk for cancers. The Center also maintains a High-Risk Familial Cancer Registry of some 13,988 individuals from the statewide region whose family histories often extend back many generations. At the Center, medical geneticists and certified genetic counselors work collaboratively with multidisciplinary teams of experts (oncologists, radiologists, surgeons among others) throughout the system. Additionally, our Center provides community genetics outreach and education services.

## Immunovia, Inc.

Address : 26 Forest Street, Suite 110, Marlborough, MA 01752

Phone : 833.593.9522

Web : [www.immunovia.com](http://www.immunovia.com)



Immunovia is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. To achieve this mission Immunovia collaborates and engages with healthcare providers, leading experts, and patient advocacy groups focused on individuals at increased risk for pancreatic cancer.

## Impact Genetics (A specialty division of LabCorp U.S.A.)

Address : 115 Midair Court, Brampton, Ontario, Canada, L6T5V1

Phone : 1-877-624-9769

Web : [www.impactgenetics.com](http://www.impactgenetics.com)



Impact Genetics, the leader in Retinoblastoma somatic and germline testing since 1999 in Canada/North America, is a specialty division of LabCorp U.S.A. As a part of the LabCorp family, Impact Genetics now offers a select range of specialty tests to US customers including the MLH1/MSH2/MSH6/PMS2/EPCAM Somatic Tumor Mismatch Repair Sequencing and Deletion/Duplication Test. Directly available via Impact Genetics, this text includes comprehensive 3rd party insurance pre-authorization and billing support provided by LabCorp. To learn more about this test, contact [info@impactgenetics.com](mailto:info@impactgenetics.com).

# SPONSORS & EXHIBITORS DIRECTORY



2024 CGA-IGC  
Annual Meeting

November 14-16, 2024

Philadelphia

## Invitae

Web : <https://www.invitae.com/>

Invitae is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.

To learn more, visit [invitae.com](https://www.invitae.com) and follow for updates on Twitter, Instagram, Facebook and LinkedIn @Invitae



## Jacqueline Rush Foundation

Address : 2605 Camino Tassajara #3511 Danville, CA. 94526

Phone : 1 408-657-7874

Web : <https://www.jrushfoundation.org/>

The Jacqueline Rush Foundation's mission is to save lives by improving public and medical community awareness of Lynch Syndrome, raise funds for Lynch Syndrome research, and to provide education and support for Lynch Syndrome Carriers and their families. The Jacqueline Rush Foundation was founded in honor of Jacqueline Rush who tragically lost her life at the age of 23 from Lynch Syndrome related colorectal cancer because she didn't know Lynch Syndrome was in her family's genes.



## Johnson & Johnson (J&J)

Address : 920 Route 202, Raritan, NJ 08869

Web : [www.jnj.com](http://www.jnj.com)

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at <https://www.jnj.com/>.

**Johnson & Johnson**

# SPONSORS & EXHIBITORS DIRECTORY



2024 CGA-IGC  
Annual Meeting

November 14-16, 2024

Philadelphia

## Lynsight

Address : FI25582879, Arabiankatu 12, 00560 Helsinki, Finland  
Phone : +358 40 660 2622  
Web : <https://lyn sightlabs.com/>



Lynsight, a leader in Lynch syndrome diagnostics, is committed to reducing cancer mortality rates with our simple and accurate diagnostic method for inherited MMR deficiency, DiagMMR. Our mission is to empower families and healthcare professionals to make better-informed decisions for cancer prevention. Lynsight has been on the forefront of Lynch syndrome research for over 10 years, driven by the mission to find a better way to help people prevent cancer. What started in the labs of the University of Helsinki in the 1990s will not stop until every potential Lynch syndrome case is tested every year.

## Mayberry Memorial

Web : <https://www.mayberrymemorial.org/>

Mayberry Memorial was founded in 2011 in memory of Steve Mayberry, who lost his battle with colon cancer in 2010 at the age of 50. Mayberry Memorial's flagship program, Project Conquer, provides resources and funding for qualifying applicants to receive genetic counseling and genetic testing for Lynch syndrome. Steve never knew he had Lynch syndrome, but if he had, he could have taken preventable measures with his health to still be with us today. His story inspired Project Conquer, where we hope to raise awareness for Lynch syndrome and identify other Lynch syndrome Previvors before they fall victim to his same fate.



## My Faulty Gene

Web : <https://myfaultygene.org/>

My Faulty Gene is a national nonprofit organization which provides information and assistance to any individual whose personal and/or family medical history suggest genetic testing might be helpful in identifying an increased risk of disease due to a genetic mutation. We believe that everyone in need of genetic testing should have access to it, including family members of individuals with a known mutation.

MY FAULTY GENE



genetic testing saves lives

# SPONSORS & EXHIBITORS DIRECTORY



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

*Philadelphia*

### Myriad Genetics

Address : 322 North 2200 West, Salt Lake City, UT 84116

Web : [www.myriad.com](http://www.myriad.com)



Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit [www.myriad.com](http://www.myriad.com).

### Natera

Web : [www.natera.com](http://www.natera.com)



Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 200 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. Visit [www.natera.com](http://www.natera.com).

### The National Comprehensive Cancer Network

Web : <https://www.nccn.org/>



The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives.

### The New Zealand Familial Gastrointestinal Cancer Service

Address : Auckland City Hospital, Auckland 1142, New Zealand

Phone : +64 0800 554 555

Web : [www.nzfgcs.co.nz](http://www.nzfgcs.co.nz)



The New Zealand Familial Gastrointestinal Cancer Service is a national service funded by Health New Zealand | Te Whatu Ora (Health NZ). We are a multidisciplinary team of senior nurses, genetic counsellors, gastroenterologists and colorectal surgeons that specialises in the assessment and management of familial gastrointestinal cancer syndromes

# SPONSORS & EXHIBITORS DIRECTORY



## 2024 CGA-IGC Annual Meeting

November 14-16, 2024

*Philadelphia*

### OSUCCC – James

The Ohio State University Comprehensive Cancer Center –James Cancer Hospital and Solove Research Institute (OSUCCC – James) strives to create a cancer-free world by integrating research with excellence in education and patient-centered care, a strategy that leads to better cancer prevention, detection and treatment. The OSUCCC – James is one of 53 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and maintains the NCI’s highest rating of “exceptional.” As the cancer program’s 356-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet® designation, the highest honor an organization can receive for quality patient care and professional nursing practice.



### Penn Medicine’s Lynch Syndrome Program

Address : 3400 Civic Center Boulevard, Philadelphia, PA 19104

Web : [www.med.upenn.edu/lynchsyndromesymposium](http://www.med.upenn.edu/lynchsyndromesymposium)

Penn Medicine’s Lynch Syndrome Program is a comprehensive program dedicated to advancing education, research, treatment, and prevention of Lynch syndrome-related cancers. Its annual Penn Medicine Lynch Syndrome Symposium provides an opportunity to hear directly from a multi-disciplinary team of experts at the forefront of ground-breaking research and discovery, while the program’s newsletter and webinars share year-round updates on clinical and research advancements in the field.



### Penn Medicine (Basser & ACC)

Address : 3400 Civic Center Blvd, Philadelphia, Pennsylvania, US, 19104

Web : <https://www.pennmedicine.org/>  
<https://www.basser.org/>

Penn Medicine’s Abramson Cancer Center is a world leader in patient care, education and cancer research, including the Basser Center for BRCA as the first comprehensive center for the research, treatment and prevention of BRCA-related cancers. With help from the Abramson Cancer Center team of scientists, geneticists, and physicians, the Basser Center continues to advance genetics research of certain hereditary cancers in hopes that we one day see a world free of their devastating effects. As a leader in raising awareness, we are a place where families can turn for education and clinical care. Learn more at [PennMedicine.org](http://PennMedicine.org) and [Basser.org](http://Basser.org).



# SPONSORS & EXHIBITORS DIRECTORY



2024 CGA-IGC  
Annual Meeting

November 14-16, 2024

Philadelphia

## Project DNA

Address : 23 Upper Ragsdale Dr., Monterey, CA, 93940

Web : [www.projectdna.org](http://www.projectdna.org)



Project DNA's mission is to create systematic programs to identify patients at risk for hereditary cancer syndromes every time they touch the healthcare system, after obtaining informed consent, test those patients found to be at high risk and then survey those patients who test positive according to NCCN guidelines. In conjunction with identifying patients with hereditary cancer syndromes, Project DNA also focuses on educating physicians and other healthcare providers about managing patients with these syndromes.

## SpringWorks Therapeutics

Address : 100 Washington Blvd, Stamford, CT 06902


Web : [www.springworkstx.com](http://www.springworkstx.com)



SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. For more information, visit [www.springworkstx.com](http://www.springworkstx.com) and follow @SpringWorksTx on Twitter and LinkedIn.

## Tempus

Web : <https://www.tempus.com/>



AI-enabled precision medicine. Bringing the power of data and artificial intelligence to healthcare.


OFFER PATIENTS  
**A CHOICE**  
IN BOWEL PREPARATION

**SUTAB**<sup>®</sup>

(sodium sulfate, magnesium sulfate, and potassium chloride)  
Tablets

1.479 g/0.225 g/0.188 g

**THE TABLET CHOICE**



Tablets and packaging not shown actual size.

SEE FULL PRESCRIBING  
INFORMATION AND  
MEDICATION GUIDE  
FOR SUTAB AT  
**SUTAB.COM**



**SUFLAVE**<sup>™</sup>

(polyethylene glycol 3350,  
sodium sulfate, potassium chloride,  
magnesium sulfate, and sodium  
chloride for oral solution)  
178.7 g/7.3 g/1.12 g/0.9 g/0.5 g

**THE FLAVOR CHOICE**



Packaging not shown actual size.

SEE FULL PRESCRIBING  
INFORMATION AND  
MEDICATION GUIDE  
FOR SUFLAVE AT  
**SUFLAVE.COM**





**Dana-Farber**  
Cancer Institute

Lynch Syndrome Center

# Save the Date for the **Lynch Syndrome Scientific Symposium**

**Wednesday, April 16, 2025**

**Dana-Farber Cancer Institute  
Boston, MA**

*In-person and virtual options are available*

A symposium dedicated to researchers and clinicians focused on the study and clinical care of individuals with Lynch syndrome.

Hosted by **Dr. Matthew Yurgelun** and **Dr. Sapna Syngal**

## **Featuring sessions on the following topics:**

- Identification and Risk Assessment of Lynch Syndrome
- Early Detection and Screening Approaches in Lynch Syndrome
- Understanding Tumor and Host Biology
- Immunotherapy and Immune Prevention

## **Keynote Speaker:**

**Prof. Sir John Burn**, Newcastle University  
*Updates from the CAPP3 Study*



## **Speakers will include:**

**Zsofia Stadler, MD**, Memorial Sloan Kettering Cancer Center

**Robert Hüneberg, MD, PhD**, University of Bonn - Germany

**Emma Crosbie, BSc, MBChB, PhD**, University of Manchester - UK

**Megan Hitchins, PhD**, Cedars-Sinai Medical Center

**Ajay Bansal, MD**, University of Kansas Cancer Center

**Timothy Yen, MD**, Loma Linda University Health

**Frank Sinicrope, MD**, Mayo Comprehensive Cancer Center

*And more*



Scan here to **register**  
for the symposium



Call for **Abstracts!** Scan here for  
more information and to submit



Email: [LynchSyndromeCenter@dfci.harvard.edu](mailto:LynchSyndromeCenter@dfci.harvard.edu)

ADD PEACE OF  
MIND TO YOUR  
TREATMENT PLAN.

THE RISKGUARD™ TEST

LEARN MORE



**riskguard**™  
Hereditary Cancer Test

TURN GENETIC  
INFORMATION  
INTO INSIGHTS.

THE RISKGUARD™ TEST

LEARN MORE



**riskguard**<sup>™</sup>  
Hereditary Cancer Test



**immunovia**

**Immunovia is committed  
to saving lives through  
the early detection of  
pancreatic cancer.**

**Immunovia's next-generation test to detect PDAC  
at stage 1 and 2 shows tremendous promise.  
We are excited to work with leading clinicians to  
meet the need for a convenient, affordable blood  
test to detect pancreatic cancer.**

Please join us Friday **November 15th at 12:30pm**  
for an Educational Symposium:

## **Increasing Access to Pancreatic Cancer Screening Lessons Learned from a Community-Based High-Risk Screening Program**

### **Topics of discussion will be:**

#### **The Landscape of Early Detection Tests in High-Risk Pancreatic Cancer Ora Gordon, MD, MS, FACMG**

*Regional Medical Director, Clinical Genetics & Genomics  
Program, Providence Health Professor of Genetics, Saint  
John's Cancer Institute Clinical Professor, UCLA Geffen  
School of Medicine*



#### **Implementing a High-Risk Pancreatic Cancer Surveillance Program in a Community Setting Miles Picus, MS, LCGC**

*Genetic Counselor and Pancreatic Cancer High-Risk  
Screening and Prevention Program Coordinator, Clinical  
Genetics & Genomics Program, Providence Health*




**LUNCH WILL BE PROVIDED**

Supported by



# We believe health is everything



We're working at the intersection of science and technology to build a world where complex diseases are prevented, treated and cured. Where treatments are smarter and less invasive. And solutions are personal.

Learn more at [JNJ.com](https://www.jnj.com).

## Johnson & Johnson



Lynsight

# A PATH FORWARD

FOR FAMILIES WITH  
HEREDITARY CANCER

Find out more at [LYNSIGHTLABS.COM](https://LYNSIGHTLABS.COM)



# A PATH FORWARD

## FOR FAMILIES WITH HEREDITARY CANCER

Lynch syndrome is one of the most common causes of hereditary cancers but difficult to diagnose. Lynsight offers a new way to test for Lynch syndrome, so healthcare providers can focus on the path instead of the problem.

Find out more at [LYNSIGHTLABS.COM](https://LYNSIGHTLABS.COM)

The logo for Lynsight, featuring the word "Lynsight" in a bold, sans-serif font. The "y" is teal, and the "sight" is black. Above the "i" in "sight" is a stylized sunburst icon with a red dot in the center and teal lines radiating outwards.

# Introducing the Hereditary Cancer Alert Program

Identify more at-risk patients and families for precision care in oncology

Learn more here



Natera created the Hereditary Cancer Alert Program (HCAP) to automatically flag Signatera™ patients that meet testing guidelines via an opt-in monthly report. **At-risk patients tested increased by up to 2x in cancer centers.**

## Choose Empower™ for customizable and accessible hereditary cancer testing:

- Pre-curated panels and easy-to-use functionality for customization options up to 191 genes.
- RNA analysis for variant resolution with no additional sample or cost required.
- Same-size panel Family Testing Program (FTP) at no additional cost.
- Accessible and transparent pricing, pricing cap and cash pay options.

## The leader in molecular diagnostics



**20+ years**  
in operation



**>10 million**  
tests requisitioned



**200+**  
peer-reviewed  
publications

1. Kurian, A., Abrahamse, P., Furgal, A., et al. Germline Genetic Testing After Cancer Diagnosis. *JAMA*, E1–E9(2023). <https://doi.org/doi:10.1001/jama.2023.9526>



# Learn About An Approved Treatment for Adults with Progressing Desmoid Tumors Who Require Systemic Treatment

Presented by

**Dr. Bassan Allan**

Surgical Oncologist, South Florida Surgical Oncology  
Fort Myers, Florida

**Thursday**  
**Nov. 14, 2024**  
**12:30-1:30 PM**  
**Location:**  
**Room**  
**Liberty A**



**Dr. Bassan Allan**

The first and only FDA-approved targeted therapy for adult patients with progressing desmoid tumors who require systemic treatment

OGSIVEO CAN HELP FREE PATIENTS FROM THE GRIP OF DESMOID TUMORS

Not an actual patient. Individual results may vary.

#### Indication

OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.

#### Important Safety Information

##### Warnings and Precautions

**Diarrhea:** Diarrhea, sometimes severe, can occur in patients treated with OGSIVEO. Diarrhea occurred in 84% of patients treated with OGSIVEO, and included Grade 3 events in 16% of patients. Median time to first diarrhea event was 9 days (range: 2 to 434 days). Monitor patients and manage using antidiarrheal medications. Modify dose as recommended.

**Ovarian Toxicity:** Female reproductive function and fertility may be impaired in patients treated with OGSIVEO. Impact on fertility may depend on factors like duration of therapy and state of gonadal function at time of treatment. Long-term effects of OGSIVEO on fertility have not been established. Advise patients on the potential risks for ovarian toxicity before initiating treatment. Monitor patients for changes in menstrual cycle regularity or the development of symptoms of estrogen deficiency, including hot flashes, night sweats, and vaginal dryness.

**Hepatotoxicity:** ALT or AST elevations occurred in 30% and 33% of patients, respectively. Grade 3 ALT or AST elevations ( $>5 \times$  ULN) occurred in 6% and 2.9% of patients. Monitor liver function tests regularly and modify dose as recommended.

**Non-Melanoma Skin Cancers:** New cutaneous squamous cell carcinoma and basal cell carcinoma occurred in 2.9% and 1.4% of patients, respectively. Perform dermatologic evaluations prior to initiation of OGSIVEO and routinely during treatment.

**Electrolyte Abnormalities:** Decreased phosphate (65%) and potassium (22%) occurred in OGSIVEO-treated patients. Phosphate  $<2$  mg/dL occurred in 20% of patients. Grade 3 decreased potassium occurred in 1.4% of patients. Monitor phosphate and potassium levels regularly and supplement as necessary. Modify dose as recommended.

**Embryo-Fetal Toxicity:** OGSIVEO can cause fetal harm when administered to pregnant women. Oral administration of nirogacestat to pregnant rats during the period of organogenesis resulted in embryo-fetal toxicity and death at maternal exposures below human exposure at the recommended dose of 150 mg twice daily. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use effective contraception during treatment with OGSIVEO and for 1 week after the last dose.

##### Adverse Reactions

The most common ( $\geq 15\%$ ) adverse reactions were diarrhea (84%), ovarian toxicity (75% in the 36 females of reproductive potential), rash (68%), nausea (54%), fatigue (54%), stomatitis (39%), headache (30%), abdominal pain (22%), cough (20%), alopecia (19%), upper respiratory tract infection (17%), and dyspnea (16%).

Serious adverse reactions occurred in 20% of patients who received OGSIVEO. Serious adverse reactions occurring in  $\geq 2\%$  of patients were ovarian toxicity (4%).

The most common laboratory abnormalities ( $\geq 15\%$ ) were decreased phosphate, increased urine glucose, increased urine protein, increased AST, increased ALT, and decreased potassium.

##### Drug Interactions

**CYP3A Inhibitors and Inducers:** Avoid concomitant use with strong or moderate CYP3A inhibitors (including grapefruit products, Seville oranges, and starfruit) and strong or moderate CYP3A inducers.

**Gastric Acid Reducing Agents:** Avoid concomitant use with proton pump inhibitors and H<sub>2</sub> blockers. If concomitant use cannot be avoided, OGSIVEO can be staggered with antacids (e.g., administer OGSIVEO 2 hours before or 2 hours after antacid use).

Consult the full Prescribing Information prior to and during treatment for important drug interactions.

##### Use in Specific Populations

Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with OGSIVEO and for 1 week after the last dose.

Please see the full Prescribing Information for OGSIVEO available at this exhibit.



Learn more and  
access resources at  
[OGSIVEO.com/hcp](https://ogsiveo.com/hcp)

**Ogsiveo**  
(nirogacestat)  
150mg & 100mg tablets

**SpringWorks**  
THERAPEUTICS

© 2024 SpringWorks Therapeutics, Inc. All rights reserved. 08/24  
OGSIVEO is a registered trademark of SpringWorks Therapeutics, Inc.

# 2025 CGA-IGC Annual Meeting

The Collaborative  
Group of the Americas  
on Inherited  
Gastrointestinal  
Cancer

October 9-11, 2025  
St. Louis

**SAVE  
THE DATE**

1995

30 YEARS OF CGA-IGC

2025



[www.cgaigcmeeting.org](http://www.cgaigcmeeting.org)

#CGAIGC25



Annual Meeting  
Organizing Secretariat, PCO:  
Kenes Group, Office: M+  
Contact: [lvulkan@kenes.com](mailto:lvulkan@kenes.com)